Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients

Clinical Drug Investigation

Volumn 30, Issue 5, 2010, Pages 279-287

  Stass, Heino ^a   Delesen, Heinz ^a   Kubitza, Dagmar ^a   Mai, Ingrid ^b   Bauer, Steffen ^b   Roots, Ivar ^b  

^a BAYER PHARMA AG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYCLOSPORIN; HETEROCYCLIC COMPOUND; IMMUNOSUPPRESSIVE AGENT; MOXIFLOXACIN; QUINOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG INTERACTION; DRUG MONITORING; HUMAN; KIDNEY TRANSPLANTATION; MALE; METHODOLOGY; MIDDLE AGED;

ADULT; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; QUINOLINES;

EID: 77953238745     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/BF03256904     Document Type: Article

References (32)

1. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory fluoroquinolones'. J Antimicrob Chemother 1999; 43 Suppl. B: 1-11
2. Woodcock KM, Andrews JM, Boswell FJ, et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-6
3. Aldridge KE, Ashcraft DS. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, against clinically important anaerobes. Antimicrob Agents Chemother 1997; 41: 709-11
4. Donati M, Rodriguez Fermepin M, Olmo A, et al. Comparative in vitro activity of moxifloxacin, minocycline, and azithromycin against Chlamydia spp. J Antimicrob Chemother 1999; 43: 825-7
5. Burkhardt O, Welte T. 10 years' experience with the pneumococcal quinolone moxifloxacin. Expert Rev Anti Infect Ther 2009; 7: 645-68
6. Prabhu RM, Elliott MA, Patel R. Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacinsusceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation. Clin Infect Dis 2004; 38: 1043-5
7. Stass H, Nagelschmitz J, Moeller JG, et al. Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. Int J Clin Pharmacol Ther 2004; 42: 23-9
8. Radtke M. Bayer HealthCare AG: Wuppertal, 1999. (Data on file)
9. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl. B: 83-90
10. Stass H, Kubitza D, Halabi A, et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002; 53: 232-7
11. Czock D, Husig-Linde C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 2006; 1: 1263-8
12. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26: 940-50
13. Stass H, Buhrmann S, Mitchell A, et al. The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction. Br J Clin Pharmacol 2007; 64: 745-9
14. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21 (10 Pt 2): 253-72S
15. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents 2000; 16: 5-15
16. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P- 450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-5
17. Christians U, Sewing KF. Cyclosporin metabolism in transplanted patients. Pharmacol Ther 1993; 57: 291-345
18. Christians U, Sewing KF. Alternative cyclosporin metabolic pathways and toxicity. Clin Biochem 1995; 28: 547-59
19. Gupta SK, Bakran A, Johnson RW, et al. Cyclosporinerythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989; 27: 475-81
20. Ahmed S, Vo NT, Thalhammer T, et al. Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. J Pharm Pharmacol 2008; 60: 55-62
21. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005; 5: 987-94
22. Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by highperformance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr Biomed Appl 1997; 702: 163-74
23. Stass H, Kubitza D, Schuly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001; 40 Suppl. 1: 1-9
24. Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy-quinolone, administered to healthy subjects. Antimicrob Agents Chmoether 1998; 42 (8): 2060-5
25. Guay D. Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag 2006; 2: 417-34
26. Neuman M. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 1988; 14: 96-121
27. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101-19
28. Tavanic- 500mg tablets, summary of product characteristics. Frankfurt: Sanofi Aventis, 2007 Sep
29. Borner K, Lode H. Biotransformation of selected gyrase inhibitors [in German]. Infection 1986; 14 Suppl. 1: S54-9
30. Elston RA, Taylor J. Possible interaction of ciprofloxacin with cyclosporine A. J Antimicrob Chemother 1988; 21: 679-80
31. Nasir M, Rotellar C, Hand M, et al. Interaction between ciclosporin and ciprofloxacin. Nephron 1991; 57: 245-6
32. McLellan RA, Drobitch RK, McLellan H, et al. Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation. Clin Pharmacol Ther 1995; 58: 322-7